Frequent activating GNAS mutations in villous adenoma of the colorectum

Masayoshi Yamada, Shigeki Sekine, Reiko Ogawa, Hirokazu Taniguchi, Ryoji Kushima, Hitoshi Tsuda, Yae Kanai

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

To elucidate the role of GNAS mutations in colorectal tumourigenesis, we performed a mutation analysis in a total of 234 colorectal tumours, including adenomas, serrated lesions and adenocarcinomas. Activating GNAS mutations were found in 20 of the 24 villous adenomas (83%) but were absent in all the other tumours, except for one tubulovillous adenoma (3%) and two adenocarcinomas (3%). KRAS and BRAF mutations were always mutually exclusive. KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%). BRAF mutations were found in four villous adenomas (17%) and in the large majority of serrated lesions (81-92%), but were absent in tubular and tubulovillous adenomas. Seventeen villous adenomas (71%) harboured GNAS mutations concomitantly with KRAS or BRAF mutations. Immunohistochemically, all the villous adenomas retained mismatch repair protein expression, suggesting that they are microsatellite-stable. The current study showed that the presence of activating GNAS mutations, in association with KRAS or BRAF mutations, is a characteristic genetic feature of colorectal villous adenoma.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalJournal of Pathology
Volume228
Issue number1
DOIs
Publication statusPublished - 2012 Sep
Externally publishedYes

Fingerprint

Villous Adenoma
Mutation
Adenoma
Polyps
Adenocarcinoma
DNA Mismatch Repair
Microsatellite Repeats
Colorectal Neoplasms

Keywords

  • BRAF
  • colorectum
  • GNAS
  • KRAS
  • villous adenoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Yamada, M., Sekine, S., Ogawa, R., Taniguchi, H., Kushima, R., Tsuda, H., & Kanai, Y. (2012). Frequent activating GNAS mutations in villous adenoma of the colorectum. Journal of Pathology, 228(1), 113-118. https://doi.org/10.1002/path.4012

Frequent activating GNAS mutations in villous adenoma of the colorectum. / Yamada, Masayoshi; Sekine, Shigeki; Ogawa, Reiko; Taniguchi, Hirokazu; Kushima, Ryoji; Tsuda, Hitoshi; Kanai, Yae.

In: Journal of Pathology, Vol. 228, No. 1, 09.2012, p. 113-118.

Research output: Contribution to journalArticle

Yamada, M, Sekine, S, Ogawa, R, Taniguchi, H, Kushima, R, Tsuda, H & Kanai, Y 2012, 'Frequent activating GNAS mutations in villous adenoma of the colorectum', Journal of Pathology, vol. 228, no. 1, pp. 113-118. https://doi.org/10.1002/path.4012
Yamada M, Sekine S, Ogawa R, Taniguchi H, Kushima R, Tsuda H et al. Frequent activating GNAS mutations in villous adenoma of the colorectum. Journal of Pathology. 2012 Sep;228(1):113-118. https://doi.org/10.1002/path.4012
Yamada, Masayoshi ; Sekine, Shigeki ; Ogawa, Reiko ; Taniguchi, Hirokazu ; Kushima, Ryoji ; Tsuda, Hitoshi ; Kanai, Yae. / Frequent activating GNAS mutations in villous adenoma of the colorectum. In: Journal of Pathology. 2012 ; Vol. 228, No. 1. pp. 113-118.
@article{a6746ec066354a3491cf76c1c50c7309,
title = "Frequent activating GNAS mutations in villous adenoma of the colorectum",
abstract = "To elucidate the role of GNAS mutations in colorectal tumourigenesis, we performed a mutation analysis in a total of 234 colorectal tumours, including adenomas, serrated lesions and adenocarcinomas. Activating GNAS mutations were found in 20 of the 24 villous adenomas (83{\%}) but were absent in all the other tumours, except for one tubulovillous adenoma (3{\%}) and two adenocarcinomas (3{\%}). KRAS and BRAF mutations were always mutually exclusive. KRAS mutations were frequent in villous (67{\%}) and tubulovillous (60{\%}) adenomas but were rare or absent in tubular adenomas (6{\%}) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9{\%}). BRAF mutations were found in four villous adenomas (17{\%}) and in the large majority of serrated lesions (81-92{\%}), but were absent in tubular and tubulovillous adenomas. Seventeen villous adenomas (71{\%}) harboured GNAS mutations concomitantly with KRAS or BRAF mutations. Immunohistochemically, all the villous adenomas retained mismatch repair protein expression, suggesting that they are microsatellite-stable. The current study showed that the presence of activating GNAS mutations, in association with KRAS or BRAF mutations, is a characteristic genetic feature of colorectal villous adenoma.",
keywords = "BRAF, colorectum, GNAS, KRAS, villous adenoma",
author = "Masayoshi Yamada and Shigeki Sekine and Reiko Ogawa and Hirokazu Taniguchi and Ryoji Kushima and Hitoshi Tsuda and Yae Kanai",
year = "2012",
month = "9",
doi = "10.1002/path.4012",
language = "English",
volume = "228",
pages = "113--118",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Frequent activating GNAS mutations in villous adenoma of the colorectum

AU - Yamada, Masayoshi

AU - Sekine, Shigeki

AU - Ogawa, Reiko

AU - Taniguchi, Hirokazu

AU - Kushima, Ryoji

AU - Tsuda, Hitoshi

AU - Kanai, Yae

PY - 2012/9

Y1 - 2012/9

N2 - To elucidate the role of GNAS mutations in colorectal tumourigenesis, we performed a mutation analysis in a total of 234 colorectal tumours, including adenomas, serrated lesions and adenocarcinomas. Activating GNAS mutations were found in 20 of the 24 villous adenomas (83%) but were absent in all the other tumours, except for one tubulovillous adenoma (3%) and two adenocarcinomas (3%). KRAS and BRAF mutations were always mutually exclusive. KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%). BRAF mutations were found in four villous adenomas (17%) and in the large majority of serrated lesions (81-92%), but were absent in tubular and tubulovillous adenomas. Seventeen villous adenomas (71%) harboured GNAS mutations concomitantly with KRAS or BRAF mutations. Immunohistochemically, all the villous adenomas retained mismatch repair protein expression, suggesting that they are microsatellite-stable. The current study showed that the presence of activating GNAS mutations, in association with KRAS or BRAF mutations, is a characteristic genetic feature of colorectal villous adenoma.

AB - To elucidate the role of GNAS mutations in colorectal tumourigenesis, we performed a mutation analysis in a total of 234 colorectal tumours, including adenomas, serrated lesions and adenocarcinomas. Activating GNAS mutations were found in 20 of the 24 villous adenomas (83%) but were absent in all the other tumours, except for one tubulovillous adenoma (3%) and two adenocarcinomas (3%). KRAS and BRAF mutations were always mutually exclusive. KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%). BRAF mutations were found in four villous adenomas (17%) and in the large majority of serrated lesions (81-92%), but were absent in tubular and tubulovillous adenomas. Seventeen villous adenomas (71%) harboured GNAS mutations concomitantly with KRAS or BRAF mutations. Immunohistochemically, all the villous adenomas retained mismatch repair protein expression, suggesting that they are microsatellite-stable. The current study showed that the presence of activating GNAS mutations, in association with KRAS or BRAF mutations, is a characteristic genetic feature of colorectal villous adenoma.

KW - BRAF

KW - colorectum

KW - GNAS

KW - KRAS

KW - villous adenoma

UR - http://www.scopus.com/inward/record.url?scp=84864744918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864744918&partnerID=8YFLogxK

U2 - 10.1002/path.4012

DO - 10.1002/path.4012

M3 - Article

C2 - 22374786

AN - SCOPUS:84864744918

VL - 228

SP - 113

EP - 118

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -